In summary, in light of recent approaches to target MC1R in melanoma, we demonstrate that MC1R expression is significantly higher in melanomas than nevi, making MC1R a target worthy further evaluation in radiopharmaceutical trials. The gene discussed is MC1R; the disease is melanoma.